CYP3A4 and autoimmune disease: In addition, amenamevir is metabolized by CYP3A and has been shown to induce both CYP3A and CYP2B6,12 and we can postulate that polypharmacy in the treatment of malignancies and autoimmune diseases may have affected the efficacy of amenamevir, as well as the underlying condition.